Novo Nordisk, the world’s top maker of diabetes drugs, on Wednesday reported second-quarter operating profit broadly in line with forecasts, but said prices in the key U.S. market would be lower next year. https://www.reuters.com/article/us-novo-nordisk-results/novo-nordisk-sees-lower-u-s-prices-next-year-second-quarter-profit-in-line-with-forecasts-idUSKBN1KT0GZ
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the prices of 100 of its products since the beginning of the year, Novartis has followed suit, pledging to freeze any increases in its own pricing until the end of the year.
read more http://www.pharmafile.com/news/518041/novartis-follows-pfizers-lead-pledges-no-price-hikes-2018
CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis’ CAR-T drug Kymriah, according to a spokesperson for the company. https://www.fiercepharma.com/pharma/cms-cancels-value-based-pricing-plan-novartis-kymriah-report
Sanofi’s net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies. https://www.fiercepharma.com/pharma/sanofi-tweaks-pricing-policy-discloses-8-4-net-price-decline-2017
The price lists may still be confusing to consumers, though, because standard rates are like list prices and don’t reflect what insurers and government programs pay. “Given the inherent complexity of hospital billing, making prices easy to understand is clearly a lot easier said than done,” Shawn Gremminger, of Families USA. https://khn.org/morning-breakout/hospitals-to-be-required-to-post-prices-online-as-part-of-cms-push-to-increase-transparency/
This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models
(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing. https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans
Congress hasn’t made any progress on drug pricing legislation, but that hasn’t stopped the government from acting. Now, FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business. http://www.fiercepharma.com/regulatory/fda-advances-price-competition-push-by-prioritizing-certain-generic-applications
The United States is the global leader in biomedical innovation, discovering more new cures than … http://www.biotech-now.org/health/2017/09/new-infographic-a-response-to-a-better-deal-on-drug-pricing